nature is pre-wired...nuture is influenced. creating impact for better health worldwide

Using our operations expertise to drive performance, increase revenue, and enhance the bottom line. 

Access to large network of co-investors and smart value adding money. Strong Ties and integration within the venture exchange ecosystem.
Close relationships with Fund Managers, Brokers and Service Providers. 

Proven ability to raise capital and engage value adding investors.  Allowing an efficient raise of  capital that supports your business growth.  

Considering costs, timing and tax, corporate, and securities law – we provide valuable insight to support our companies in making the right decisions.

Maximizing value by assisting with product launch, marketing, sales  market access.  

• Merger & acquisition
• Co-investment opportunities
• License agreements
• Agency distribution
• Strategic partnerships and joint ventures
• In-house ventures

Helping biotech companies across the entire value chain, from early-stage companies getting initial funding to established companies launching into international markets, publicly. 

Where other venture capital and investment firms lack the experience or interest in the nutraceutical market, we welcome new partnerships with like-minded business professionals and industry researchers, offering our expertise in financing, management, marketing and distribution for nutraceutical products. 

04-May-2023 By Ben Hargreaves

Seres, together with partners Nestle Health Science, receive approval for its microbiome therapeutic to prevent recurrence of C. difficile infection.

 GLP-1 obesity treatments like Ozempic may help restore natural… 

 By Robby Berman on May 15, 2023 — Fact checked by Catherine Carver, MPH 

A new study finds that GLP-1-based weight-loss drugs directly re-activate critical cancer-fighting immune cells that have become defective due to obesity. The study’s authors assert that this occurs in addition to the cancer-preventing weight-loss effect of GLP-1 drugs. 

 Early signs of Parkinson's found in gut microbiome of patients with… 

 By Erika Watts on May 12, 2023 — Fact checked by Alexandra Sanfins, Ph.D. 

 The gut microbiome may hold the key to diagnosing Parkinson’s disease early.  

 Low-dose aspirin had been a popular prevention measure, but as more evidence has accumulated its benefit has come into question.  

 By 

Allison Aubrey, Will Stone

New guidance from the U.S. Preventive Services Task Force says people over the age of 60 should not start taking daily, low-dose aspirin to prevent cardiovascular events like heart attacks or strokes. 

Certified Organic now accounts for 6% of total food sales in the U.S., according to a new Organic Trade Association survey. 

By

Nutraceuticals World Article 

Organic Trade Association Survey